Skip to main content
. 2011 Jun 15;7(3):282–292. doi: 10.5664/JCSM.1074

Figure 6.

Figure 6

Mean (SD) change from baseline in daily (a) wake time after sleep onset and (b) total sleep time on the PghSD by visit (mITT Population)

(a) Adjusted mean treatment difference, GEn compared with placebo at Week 12 LOCF: GEn 1200 mg, –9.8 (95% CI: –15.5, –4.2; p = 0.0007); GEn 600 mg, –7.6 (95% CI: –13.3, –2.0; p = 0.0081). **p < 0.001; *p < 0.01; †p < 0.05. (b) Adjusted mean treatment difference, GEn compared with placebo at Week 12 LOCF: GEn 1200 mg, 0.2 (95% CI: −0.1, 0.6; p = 0.1161); GEn 600 mg, 0.1 (95% CI: −0.2, 0.4; p = 0.6778). *p < 0.01; †p < 0.05. CI, confidence interval; GEn, gabapentin enacarbil; LOCF, last observation carried forward; mITT, modified intent-to-treat; PghSD, Pittsburgh Sleep Diary; SD, standard deviation.